Haleon (HLN) Fundamentals 2026 — P/E 19.7x, Revenue Analysis | SniperIQ
Haleon (HLN) is a GB-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of $43.5B, trading at $9.88 on the NYSE. This SniperIQ fundamentals page covers Haleon's valuation (P/E 19.7x, P/B 2.0x), profitability (net margin 15.1%), revenue (£11.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Haleon's market cap?
Haleon (HLN) has a market capitalization of approximately $43.5B, trading at $9.88 on the NYSE. Market cap moves with the live share price.
What is Haleon's P/E ratio?
Haleon's trailing twelve-month P/E ratio is 19.7x, with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Haleon?
Haleon runs a net profit margin of 15.1%, a gross margin of 64.8%, and an operating margin of 21.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Haleon generate?
Haleon reported revenue of £11.0B for fiscal year 2025, with net income of £1.6B and earnings per share (EPS) of 0.36. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Haleon pay a dividend?
Haleon offers a trailing dividend yield of about 1.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Haleon financially healthy?
Haleon carries a debt-to-equity ratio of 0.52x and a current ratio of 0.92x, with a market beta of 0.24. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Haleon a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Haleon (HLN) the key facts are: market cap $43.5B, P/E 19.7x, revenue £11.0B, 52-week range 8.65-11.28. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Haleon's full fundamentals live
Get Haleon's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.